Continuous glucose monitoring may reduce mortality and hypoglycemia in ICU patients compared to point of care testing

This meta-analysis examined the use of continuous glucose monitoring in critically ill patients within intensive care units. The analysis pooled data from multiple studies involving a total sample size of 2027 patients. The primary comparison was between continuous glucose monitoring and standard point of care blood glucose measurements. The study setting encompasses various intensive care unit environments where glycemic control is a critical management goal. The authors aimed to determine if continuous monitoring offers clinical advantages over traditional intermittent testing methods.

The primary outcome of interest was mortality. The pooled analysis yielded a relative risk of 0.61 for mortality with continuous glucose monitoring compared to point of care testing. The 95% confidence interval for this relative risk ranged from 0.35 to 1.04. This interval suggests a potential reduction in mortality, although the upper bound approaches unity. Absolute numbers for mortality events were not reported in the source data. The direction of the effect indicates a trend toward lower mortality rates in the continuous monitoring group.

A secondary outcome assessed was the incidence of hypoglycemia. The analysis found a relative risk of 0.44 for hypoglycemia with continuous glucose monitoring. The 95% confidence interval for this result was 0.23 to 0.82. This finding suggests a substantial reduction in hypoglycemic events. Absolute numbers for hypoglycemia events were not reported. The direction of the effect clearly favors continuous monitoring for preventing low blood sugar episodes.

Safety and tolerability data were not reported in the included studies. Serious adverse events were not reported. Discontinuation rates due to adverse events were not reported. Tolerability profiles were not reported. Consequently, a comprehensive safety assessment cannot be derived from this meta-analysis. The absence of this data limits the ability to weigh risks against potential benefits.

Several methodological limitations were identified. The evidence is rated as very low certainty according to GRADE criteria. There was a lack of standardization of glucose measurements across the included studies. Different management strategies were employed in the various trials, which introduces heterogeneity. These factors contribute to the uncertainty surrounding the clinical implications of the findings.

The results indicate that continuous glucose monitoring may reduce mortality and hypoglycemia. However, the evidence is very uncertain. Potential benefits are not confirmed with high confidence. Larger, more rigorous trials are needed to establish definitive efficacy. The current data should be interpreted with caution when making practice decisions.

Key questions remain unanswered regarding the optimal management strategies for critically ill patients. The impact of different management protocols on the observed outcomes is unclear. The generalizability of these findings to all ICU settings requires further investigation. Clinicians must weigh the potential for reduced hypoglycemia against the lack of safety data and very low certainty evidence.

In summary, while the relative risk estimates are promising, the overall certainty of the evidence is very low. The lack of standardization and variation in management strategies complicates the interpretation of results. Until larger trials are conducted, the use of continuous glucose monitoring should be considered investigational rather than standard of care.